Gene therapy pioneer Kathy High leaves AskBio

Kathy High, a scientist and executive who led the development of the first gene therapy approved in the U.S., has left Bayer subsidiary AskBio two years after joining.

An AskBio spokesperson confirmed her departure, adding in an email that High “decided to leave AskBio to begin a sabbatical at Rockefeller University and spend more time with her family, before focusing on ventures in new spaces.”

High, in a brief interview, didn’t comment directly on her reasons for leaving but noted she is now a visiting fellow at Rockefeller University and praised the biotech and its technology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In